Skip to content

Clinical pharmacological test of calcium alginate capsules -Optimization study of postprandial serum triglyceride elevation suppression effect (additional preliminary study)-

Clinical pharmacological test of calcium alginate capsules -Optimization study of postprandial serum triglyceride elevation suppression effect (additional preliminary study)- - Optimization test of postprandial serum triglyceride elevation suppression effect of calcium alginate capsules (additional preliminary study).

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000052532
Enrollment
9
Registered
2023-10-20
Start date
2023-10-20
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy subjects

Interventions

Stage1: Placebo capsule Stage2: Test substance A capsule Stage3: Test substance B capsule Fat Loading Food d: Corn Oil Suspended with 3% Gum Arabic After eating the fat loading food within 3 min

Sponsors

Takasaki University of Health and Welfare
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Males and females aged 20 years or older at the time of informed consent. In principle, those whose fasting blood TG level at the time of screening test is less than 150mg/dL. Those who fully understand the purpose and safety of this research specified in the research cooperation consent form and have obtained consent.

Exclusion criteria

Exclusion criteria: Persons receiving treatment, medication, or lifestyle guidance from a doctor due to dyslipidemia or diabetes. People who regularly use medicines, health foods, or supplements that affect blood lipids. Persons who have some kind of disease and are receiving medication and are deemed unsuitable as subjects by the research doctor. Persons who may have allergic symptoms related to rubber or latex. Persons who may develop allergic symptoms regarding fat-loaded foods (corn oil, etc.). Persons whose HIV antigen/antibody, HBs antigen, HCV antibody, or syphilis test result was positive at the time of screening. Persons with obvious abnormalities found in hematological or biochemical tests. Those who are pregnant, wish to become pregnant during the test, or are breastfeeding. Persons whose TG delta C3h (estimated TGCmax) is less than 30 mg/dL in the screening test. Those who have been diagnosed with bronchial asthma and are receiving treatment, or those who have received treatment in the past.

Design outcomes

Primary

MeasureTime frame
The area under the curve (AUC) of the postprandial serum triglyceride.

Secondary

MeasureTime frame
The maximum concentration (Cmax) of the postprandial serum triglyceride. The serum triglyceride level (before, 60, 90, 120, 240 and 360 minutes after the fat food load).

Countries

Japan

Contacts

Public ContactSatsuki Kimura

Takasaki University of Health and Welfare Faculty of Pharmacy

s-kimura@takasaki-u.ac.jp0273521180

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026